Skip to main content

Table 1 Primers and restriction endonucleases for the CYP450 polymorphisms genotyping

From: Association of cytochrome P450 genetic polymorphisms with neoadjuvant chemotherapy efficacy in breast cancer patients

Polymorphism

Oligonucleotide primers

Amplicone

Restriction endonucleases

Restriction products, b.p.*

 CYP3A5*3  (intron 3)

f 5'-catcagttagtagacagatga-3'

293

Ssp I

148 125 20

r 5'-ggtccaaacagggaagaaata-3'

(168 125)

 CYP3A4*1B  (5'-NTR)

f 5'-tccaggcataggtaaagatc-3'

111

Acc 36 I

111

r 5'-aatctattaaatcgcctctcac-3'

(85 26)

 CYP3A4*2  (exon 6)

f 5'-ttttttggatccattctttgtc-3'

124

Bst MA I

98 26

r 5'-ttttaagtggatgaattacatggt-3'

(124)

 CYP2C9*2  (exon 3)

f 5'-cactggctgaaagagctaacagag-3'

372

Asp S9 I

179 119 74

r 5'-gtgatatggagtagggtcacccac-3'

(253 119)

 CYP2C9*3  (exon 7)

f 5'-aggaagagattgaacgtgtga-3'

130

ERh I

130

r 5'-ggcaggctggtggggagaaggccaa-3'

(104 26)

 CYP2C19*2  (exon 5)

f 5'-ccagagcttggcatattgta-3'

230

Sma I

109 121

r 5'-gaagcaatcaataaagtcccga-3'

(230)

 CYP2C19*3  (exon 4)

f 5'-ctgggctgtgctccct-3'

147

BamH I

128 19

r 5'-acttggccttacctggct-3'

(147)

 CYB2B6*5  (exon 9)

f 5'-aatacccccaacataccacatc-3'

121

Bst F5 I

105 16

r 5'-gcggggagtcagagccatt-3'

(121)

 CYP2C8*2  (exon 5)

f 5’-aaagtaaaagaacaccaagc-3’

167

Kzo9 I

69 65 33

r 5’- aaacatccttagtaaattaca-3’

(98 69)

 CYP2C8*3  (exon 3/8)

f 5’- aggcaattccccaatatctc-3’

467

BseR I

310 111 46

r 5’-caggatgcgcaatgaagac-3’

(356 111)

  1. * - fragments of the wild type alleles, fragments of the mutant type alleles parentheses.